Clinical Trial Update: Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck [Phase 1]

View source ↗

Summary

Phase 1 trial update on intratumoral PV701 for patients with advanced or unresectable recurrent squamous cell carcinoma of the head and neck, covering multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Nasopharynx
• Squamous Cell Carcinoma of the Oropharynx

Drugs mentioned

• PV701

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Status: TERMINATED